About Ascendo
Our novel approach optimizes and reinvigorates the natural, innate immune pathways to deliver comprehensive anti-tumor responses and restore immune balance in autoimmune diseases. With each new therapy, we aim to overcome the limitations of existing treatments and achieve meaningful, lasting benefits for patients across oncology and immunology.
ASD141 is a novel, innate immune checkpoint inhibitor that commands the innate immune system to coordinate a renewed attack on solid tumors. Alongside it, ASD001 targets autoimmune diseases by rebalancing overactive myeloid cells through selective innate immune modulation. Together, these first-in-class therapeutics represent a diverse pipeline focused on impactful innovation in both immuno-oncology and autoimmune indications.
Our Mission
We develop first-in-class immunotherapies by targeting novel innate immune checkpoints.
Our lead asset, ASD141, is designed to overcome resistance in solid tumors by reprogramming the tumor microenvironment. ASD001 restores immune balance to treat autoimmune diseases, while ASD111 is a small molecule program expanding our platform.
We are advancing a differentiated pipeline to deliver transformative outcomes for patients and strategic value for partners.
Breakthrough Science
Our lead product, ASD141, is a powerful immunotherapy targeted to optimize the complex interactions between the innate and the adaptive immune system.
ASD141 works by blocking TLT-1, a key regulatory protein that induces the immune suppressive environment in the tumor. Blocking TLT-1 binding to receptor CD11b reinvigorates the innate cells that coordinate an immune response in the tumor microenvironment. Our anti-TLT-1/CD11b approach has infinite potential to be used both as monotherapy and to help improve the safety and efficacy of existing treatments when used in combination.
Our Team
Our multidisciplinary team brings deep expertise in immunotherapy-based drug development, translational clinical research, and biotech business development.
Learn more about our work here.
About Us
Partner of Choice for Immunotherapy Innovation
Ascendo Biotechnology is a partner of choice for novel immunotherapies targeting the interplay between innate and adaptive immunity.
We are actively seeking strategic partners to accelerate the development and commercialization of ASD141 and ASD001.
To explore partnership opportunities, please contact us.